Is bioAffinity Technologies, Inc. (BIAFW) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| DJIM | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| MSCI | 23.0% / 33% | 17.0% / 33% | 17.5% / 33% | 0.19% / 5% | ✓ HALAL |
| S&P | N/A | N/A | N/A | N/A | ? INSUFFICIENT DATA |
| FTSE | 23.0% / 33% | 17.0% / 33% | 17.5% / 50% | 0.19% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 31.4% | |
| Operating Margin | -196.9% | |
| Net Margin | -242.0% | |
| Return on Equity (ROE) | -301.8% | |
| Return on Assets (ROA) | -75.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$9M |
| Free Cash Flow | -$9M |
| Total Debt | $1M |
| Debt-to-Equity | 15.9 |
| Current Ratio | 2.6 |
| Total Assets | $11M |
Price & Trading
| Last Close | $0.38 |
| Beta | 2.4 |
|
52-Week Range
$0.39
| |
About bioAffinity Technologies, Inc. (BIAFW)
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Related Halal Stocks in
Frequently Asked Questions
Is bioAffinity Technologies, Inc. (BIAFW) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), bioAffinity Technologies, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is bioAffinity Technologies, Inc.'s debt ratio?
bioAffinity Technologies, Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 23.0%.
What are bioAffinity Technologies, Inc.'s key financial metrics?
bioAffinity Technologies, Inc. has a market capitalization of N/A, and revenue of $6M. The company maintains a gross margin of 31.4% and a net margin of -242.0%. Return on equity stands at -301.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.